To efficiently capture these plasma ofCS glycans, we optimized an ELISA assay with different capture and detection pairs (anti- CD44, -CSPG4, -SDC1, and rVAR2), and tested their performance of detection ofCSPGs in plasma of malignant tumor patients. Here, SDC1 is linked to cancer.